Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

5-Fluorouracil

5-Fluorouracil
Contact us for more batch information
Select Batch
Purity:100%
Resource Download

5-Fluorouracil

Catalog No. T0984Cas No. 51-21-8
5-Fluorouracil (5-FU) is a uracil analog, an inhibitor of DNA synthesis. 5-Fluorouracil has antitumor activity and affects pyrimidine synthesis through inhibition of thymidylate synthase. 5-Fluorouracil causes apoptosis and autophagy.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
100 mg$30In Stock
1 g$48In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "5-Fluorouracil"

Product Introduction

Bioactivity
Description
5-Fluorouracil (5-FU) is a uracil analog, an inhibitor of DNA synthesis. 5-Fluorouracil has antitumor activity and affects pyrimidine synthesis through inhibition of thymidylate synthase. 5-Fluorouracil causes apoptosis and autophagy.
In vitro
METHODS: Human cardiomyocytes HCM, human umbilical vein endothelial cells HUVE, and human colon cancer cells HCT116 and HT29 were treated with 5-Fluorouracil (0.01-1000 µM) for 24-96 h, and the growth inhibition of the cells was detected by MTT.
RESULTS: The EC50 of 5-Fluorouracil on HCM, HUVE, PHCT116 and HT29 cells were 4.866 μM, 3.832 μM, 13.72 μM and 106.8 μM, respectively, at 72 h. [1]
METHODS: Smooth muscle cells were treated with 5-Fluorouracil (0.05-10 mM) for 24 h. Apoptosis was detected using Flow Cytometry.
RESULTS: 5-Fluorouracil at concentrations of 0.1, 1, and 10 mM induced apoptosis in cultured smooth muscle cells after 24 h of treatment, and the apoptotic cells were detached from the culture dishes. [2]
METHODS: Human colon cancer cells SW620 were incubated with 5-Fluorouracil (13 μg/mL) for 24-48 h. ALP activity was detected using an ALP detection kit.
RESULTS: Alkaline phosphatase (ALP) has been used to monitor the differentiation effects of certain anticancer compounds. Untreated SW620 cells showed relatively low ALP activity, while in cells treated with 13 μg/ml 5-FU, ALP activity reached high levels in a time-dependent manner. [3]
In vivo
METHODS: To detect the antitumor activity in vivo, 5-Fluorouracil (10-40 mg/kg) was injected intraperitoneally once a day for ten days into mice bearing ascites hepatocellular carcinoma tumor H22.
RESULTS: 5-Fluorouracil at 10 mg/kg inhibited tumor growth while maintaining immune function in mice. 5-Fluorouracil exerts low-dose, low-toxicity antitumor effects and stimulates the host immune system. [4]
METHODS: To study 5-Fluorouracil-induced intestinal injury, 5-Fluorouracil (100-200 mg/kg) was administered as a single intraperitoneal injection to BALB/c mice.
RESULTS: The body weight and diarrhea symptoms of 5-Fluorouracil-treated animals were significantly reduced in a dose-dependent manner. Occludin and claudin-1 protein expression was significantly reduced in the 5-Fluorouracil-treated group. 5-Fluorouracil-treated group showed significantly higher NF-κBp65 protein and TNF-α mRNA expression than the control group. NF-κBp65 protein and TNF-α mRNA expression were significantly higher in the 5-Fluorouracil treated group than in the control group. [5]
Cell Research
After a 7-day habituation period, the mice were divided into three groups (vehicle group, dextrin group, and ED group; n = 6 mice per group) that had the same mean body weight (time of grouping was designated as day 0). Then, mice were treated by tail vein injections from day 0 to 4; mice in the dextrin and ED groups received 40 mg/kg/day of 5- fluorouracil (5-FU) injection 250 mg, while mice in the vehicle group received 10 mL/kg/day physiological saline, which was equivalent to the dose of 5-FU. Additionally, twice a day from day 0 to 6, ED group mice received 1.6 kcal/0.8 mL/day ED administered orally, while mice in the vehicle and dextrin groups received dextrin containing the same amount of calories. Body weight and food consumption were measured before administration of 5-FU and ED on days 0 and 7. Food consumption was measured with respect to each group. Mice were accommodated individually in specially prepared polycarbonate cages, and two or more fresh stools per mouse were scored as follows: 0, the stools were not crushed when pushed by human fingers; 1, the stools were crushed, but the core remained when pushed by human fingers; 2, the stools were crushed and the core did not remain when pushed by human fingers; 3, the stools were crushed and stuck to the fingers when pushed by human fingers; 4, the stools lost their shape just from being touched. Autopsies were conducted on day 7. After bleeding, the large intestine (the colon and rectum) was taken, and the length was measured. The lumen was washed with physiological saline, the excess water was wiped off, and specimens were weighed. Section 3 cm distal from the center of the large intestine was fixed with formalin for histological evaluation. Salivary glands (the submandibular gland and sublingual gland) were collected and weighed. The collected salivary glands were fixed with formalin, and after the tissue sections were prepared, they were stained with hematoxylin and eosin [3].
Alias5-FU, Fluorouracil, NSC 19893, 5-Fluoracil
Chemical Properties
Molecular Weight130.08
FormulaC4H3FN2O2
Cas No.51-21-8
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 1.3 mg/mL (10 mM)
DMSO: 18.33 mg/mL (140.94 mM)
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
1 mM7.6876 mL38.4379 mL76.8758 mL384.3788 mL
5 mM1.5375 mL7.6876 mL15.3752 mL76.8758 mL
DMSO
1mg5mg10mg50mg
10 mM0.7688 mL3.8438 mL7.6876 mL38.4379 mL
20 mM0.3844 mL1.9219 mL3.8438 mL19.2189 mL
50 mM0.1538 mL0.7688 mL1.5375 mL7.6876 mL
100 mM0.0769 mL0.3844 mL0.7688 mL3.8438 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords